市場調查報告書
商品編碼
1262695
呼吸系統疾病檢測市場——按檢測類型、最終用途和預測,2023-2032 年Respiratory Disease Testing Market - By Test Type, By Application By End-use & Forecast, 2023 - 2032 |
預計到 2032 年,呼吸系統疾病檢測市場的收入將顯著增長。
這是由於欠發達經濟體中吸煙者數量的增加,以及對粉塵的高度暴露。 據世界衛生組織統計,中國約有3億煙民,約佔世界煙民總數的三分之一。 吸煙者數量的顯著增加增加了這些經濟體的呼吸道疾病負擔,進一步增加了對呼吸道疾病檢測的需求。
從檢查項目來看,由於影像技術的進步,預計到2032年,影像檢查領域的呼吸系統疾病檢查市場將呈現顯著增長。 事實上,計算機斷層掃描的最新進展使 COPD 的結構異常和解剖定位可視化成為可能。
此外,許多行業參與者都在關注新產品創新,這也將有利於該細分市場的增長。 例如,2022 年 11 月,成像技術領域的全球領導者 CAREStream Health 宣布了一款新的數字 X 射線檢測器,該檢測器有助於獲取更好的解剖圖像以改善臨床結果。。
根據應用,慢性阻塞性肺疾病 (COPD) 呼吸系統疾病檢測行業預計到 2032 年估值將超過 100 億美元。 空氣污染水平上升、飲食不健康和人口老齡化導致慢性阻塞性肺病激增,增加了對呼吸系統疾病檢測的需求。 根據 CDC 的數據,COPD 影響著超過 1500 萬美國人,每年有超過 150,000 名美國人死於該病。
從銷售渠道來看,診所領域的呼吸系統疾病檢測行業預計從 2023 年到 2032 年將以相當大的複合年增長率增長。 由於對先進的、具有成本效益的呼吸檢測設備的偏好日益增加,診所的患者人流量增加了。 此外,這些設施擁有大量熟練的醫務人員,非常適合診斷和治療呼吸系統疾病。
按地區劃分,在 Siemens Healthineers、Koninklijke Philips N.V 等不斷推出新產品的推動下,2023 年至 2032 年歐洲呼吸系統疾病檢測市場的複合年增長率預計將超過 6.5%。致力於創新的主要行業巨頭。 事實上,在 2022 年 7 月,德國醫療設備製造商西門子醫療宣布推出 Mobilett Impact,這是一種移動 X 射線系統,可以在患者床邊進行肺部檢查。
Respiratory disease testing market is anticipated to register substantial revenue gains through 2032, owing to high exposure to dust particles coupled with the growing number of cigarette smokers in underdeveloped and developing economies. As per WHO, there are nearly 300 million smokers in China, which accounts for around one-third of the total number of smokers globally. The remarkable rise in the number of smokers has increased the burden of respiratory diseases in these economies, further augmenting the need for respiratory disease testing.
On the basis of the test, the respiratory disease testing market from the imaging tests segment is expected to garner significant gains through 2032, owing to advancements in imaging technologies. In fact, recent developments in computed tomography imaging have made it possible to visualize structural derangements and anatomic localization of COPD.
Moreover, many industry players are putting consolidated efforts into new product innovations, which will also favor segment growth. For instance, in November 2022, CAREstream Health, a global leader in imaging technology, unveiled new digital x-ay detectors which will help better acquire images of anatomical structures for enhanced clinical outcomes.
In terms of application, the respiratory disease testing industry from the chronic obstructive pulmonary disease (COPD) segment is poised to record a valuation of over USD 10 billion by 2032. The surging occurrence of COPD owing to rising air pollution levels, unhealthy diets, the growing geriatric population, and others has bolstered the need for respiratory disease testing. As per CDC, COPD affects over 15 million Americans and over 150,000 Americans die of the disease every year.
Based on the distribution channel, the respiratory disease testing industry from the clinics segment is poised to grow at a considerable CAGR from 2023 to 2032. The rising preference for cost-effective and advanced respiratory testing equipment has increased patient footfall in clinics. Moreover, these facilities also have a high availability of skilled healthcare professionals, making them a preferred healthcare provider for the diagnosis and treatment of respiratory disorders.
Regionally speaking, Europe respiratory disease testing market is slated to grow at over 6.5% CAGR from 2023 to 2032, owing to the strong presence of key industry giants such as Siemens Healthineers, Koninklijke Philips N.V., among others who are constantly indulged in new product innovations. In fact, in July 2022, Siemens Healthineers, a German medical device manufacturer, announced the launch of Mobilett Impact, a mobile X-ray system that can perform lung examinations at a patient's bedside.